PH
PHYOF.US IXICO plc
- Market cap
- USD 169M
- P/E
- -
- P/B
- 0.26x
- ROE
- -42.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Mar 2026.
Is PHYOF.US undervalued?
Graham numberThe Graham number of IXICO plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
IXICO plc fundamental analysis
No fundamental analysis for IXICO plc yet.
IXICO plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About IXICO plc
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such…
Full company profileIXICO plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Mar 31, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
IXICO plc annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.27M | 4.10M | 5.39M | 7.56M | 9.53M | 9.19M | 8.64M | 6.67M | 5.77M | 6.53M | 15.8M |
| Gross Profit | 1.59M | 2.31M | 3.17M | 4.94M | 5.91M | 5.53M | 4.77M | 3.27M | 2.71M | 3.18M | 8.07M |
| Operating Income | -2.16M | -1.43M | -797K | 364K | 236K | 698K | 111K | -1.44M | -2.15M | -2.55M | -4.98M |
| EBITDA | -1.82M | -1.24M | -645K | 476K | 1.29M | 1.31M | 750K | -707K | -1.68M | -2.02M | -3.96M |
| Net Income | -2.12M | -1.54M | -668K | 432K | 952K | 1.51M | 1.03M | -1.18M | -2.00M | -1.65M | -4.51M |
| EPS | -0.09 | -0.06 | -0.02 | 0.01 | 0.02 | 0.03 | 0.02 | -0.02 | -0.04 | -0.02 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 5.68M | 4.51M | 10.3M | 10.7M | 12.1M | 14.3M | 14.7M | 13.0M | 11.2M | 13.8M | 13.0M |
| Total Liabilities | 1.60M | 1.82M | 3.01M | 2.78M | 2.98M | 2.78M | 2.16M | 1.56M | 1.72M | 2.10M | 2.28M |
| Shareholders' Equity | 4.09M | 2.69M | 7.33M | 7.92M | 9.12M | 11.5M | 12.5M | 11.4M | 9.46M | 11.7M | 10.7M |
| Cash & Short-term Investments | 3.12M | 2.41M | 7.86M | 7.26M | 7.95M | 6.68M | 5.77M | 4.03M | 1.79M | 3.54M | 1.68M |
| Total Debt | - | - | - | - | 213K | 597K | 516K | 387K | 314K | 179K | 560K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.54M | -644K | 355K | -130K | 1.94M | 614K | 1.43M | 302K | -1.73M | -1.01M | -5.07M |
| Capital Expenditure | 24.0K | 21.0K | 60.0K | 217K | 1.14M | 2.15M | 2.25M | 1.96M | 471K | 870K | 485K |
| Free Cash Flow | -1.56M | -665K | 295K | -347K | 795K | -1.54M | -815K | -1.66M | -2.20M | -1.88M | -5.56M |
| Ratios | |||||||||||
| ROE | -51.9% | -57.2% | -9.1% | 5.5% | 10.4% | 13.2% | 8.3% | -10.3% | -21.1% | -14.1% | -42.0% |
| ROA | -37.3% | -34.1% | -6.5% | 4.0% | 7.9% | 10.6% | 7.0% | -9.1% | -17.9% | -11.9% | -34.6% |
| Net Profit Margin | -64.8% | -37.5% | -12.4% | 5.7% | 10.0% | 16.5% | 11.9% | -17.7% | -34.7% | -25.3% | -28.5% |
| Debt to Equity | - | - | - | - | 0.02x | 0.05x | 0.04x | 0.03x | 0.03x | 0.02x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
IXICO plc dividends
IXICO plc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:50 on Nov 27, 2013.
Who owns IXICO plc
- Insiders 4.55%
- Institutions 82.55%
- Public & others 12.91%
- Shares outstanding 219M
- Free float 40.8M
IXICO plc company profile
- Company name
- IXICO plc
- Ticker
- PHYOF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 79
- Fiscal year end
- September
- Address
- Griffin Court, London, United Kingdom, EC1A 9PN
- Phone
- 44 20 3763 7499
- Website
- ixico.com
About IXICO plc
IXICO plc provides data analytics services to biopharmaceutical industry in the United States, the United Kingdom, the Netherlands, Denmark, Switzerland, Ireland, Europe, and internationally. The company offers collection, analysis, management, and reporting on gathered clinical study data; neurological diseases data collection and analysis; and sales and marketing services. It also provides imaging contract research organization solutions, including imaging biomarkers, such as radiological reads, volumetric MRI, PET and SPECT, and advanced MRI; trial management; data analytics; post marketing surveillance and clinical diagnostics; and consultancy services. In addition, the company offers IXICO platform, an AI-enabled technology platform for neuroimaging data management and analysis. Its services are used for various therapeutic areas comprising Alzheimer's, Huntington's, Multiple Sclerosis, and Parkinson's diseases, as well as other rare neurological diseases, other Demyelinating disorders, and other Parkinsonian disorders. It has collaboration with Medidata to create neuroimaging clinical trials platform. The company is based in London, the United Kingdom.
IXICO plc management
10- Mr. Bram Goorden M.Sc.CEO & Executive Director · born 1973
- Mr. Grant Robert NashCFO, COO, Company Secretary & Executive Director · born 1976
- Prof. Daniel RueckertCo-Founder & Member of Scientific Advisory Board
- Prof. Derek Lionel Glendon Hill Ph.D.Co-Founder and President of Regulatory Science & External Relations · born 1966
- Prof. David Hawkes CPhys, FInstP, FIPEM, FREng, Ph.D.Co-Founder & Member of Scientific Advisory Board
- Prof. Joseph HajnalCo-Founder & Member of Scientific Advisory Board
- Mr. Mark AustinChief Technology Officer
- Dr. Robin WolzChief Scientific Officer
- Ms. Hannah EsfahanianHR Manager
- Mr. James ChandlerChief Business Officer